Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals, Inc. is launching a primary offering of common stock and pre-funded warrants under its effective shelf registration to raise cash for its pipeline. Investors may buy either common shares or, for certain investors, pre-funded warrants that are immediately exercisable at an exercise price of $0.0001 per share and are not expected to trade on an exchange. The company’s common stock trades on the Nasdaq Global Select Market under the symbol OLMA and last closed at $8.52 per share on November 17, 2025.
Olema plans to use the net proceeds, together with existing cash, cash equivalents, marketable securities and borrowing capacity, to continue late-stage development of its lead breast cancer candidate palazestrant (OP-1250) and its second program OP-3136, and for working capital and general corporate purposes. Based on current plans, Olema believes these resources, including this offering, will fund operations into 2028, supporting a potential U.S. commercial launch of palazestrant in late 2027 if clinical trials are successful and the FDA grants approval. Shares outstanding were 68,652,730 as of September 30, 2025.
Olema Pharmaceuticals, Inc. reported that it has terminated its existing at-the-market prospectus used for sales of its common stock under a Sales Agreement with TD Securities (USA) LLC. This means the company will no longer sell shares through that at-the-market program unless and until it files a new prospectus, prospectus supplement, or registration statement. The underlying Sales Agreement itself remains in effect, so Olema could resume at-the-market sales in the future once new offering documents are in place.
Olema Pharmaceuticals (OLMA) reported Q3 2025 results, highlighting higher operating spend as its breast cancer programs advance. The company posted a net loss of $42.2 million, compared with $34.6 million a year ago. Research and development was $40.0 million and general and administrative was $5.9 million, reflecting continued clinical activity.
Liquidity remains strong, with $329.0 million in cash, cash equivalents and marketable securities at September 30, 2025, and an additional $22.0 million available under its loan facility. Stockholders’ equity was $307.5 million. The company’s weighted average share count was 85.7 million, which includes the effect of pre-funded warrants.
Olema has an at-the-market program of up to $150.0 million established in January 2025 with no sales to date. Previously, a November 2024 private placement raised $250.0 million gross (net approximately $237.0 million). As of November 5, 2025, 68,659,923 shares were outstanding; there are 17,094,163 shares issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limits.
Olema Pharmaceuticals (OLMA) furnished an update on its business by reporting financial results for the quarter ended September 30, 2025. The company submitted a Current Report on Form 8-K under Item 2.02 and included a press release as Exhibit 99.1. The disclosure is designated as furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is incorporated by reference only if specifically stated.
Olema Pharmaceuticals (OLMA) reported updated Phase 1b/2 results for palazestrant combined with ribociclib in ER+/HER2- advanced or metastatic breast cancer. As of July 8, 2025, 72 patients were enrolled across 90 mg and 120 mg palazestrant dose cohorts alongside ribociclib 600 mg daily.
Efficacy in the 120 mg cohort (median follow-up >19 months) showed mature results with median progression-free survival (mPFS) of 15.5 months for all patients. Among those previously treated with CDK4/6 inhibitors, mPFS was 12.2 months, including 9.2 months for ESR1 wild-type tumors and 13.8 months for ESR1-mutant tumors. In the 90 mg cohort (median follow-up 10.8 months), mPFS was not reached.
The combination was well tolerated with no new safety signals, no observed drug–drug interactions, and mostly grade 1–2 adverse events, consistent with known profiles. These findings support the ongoing pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib in frontline ER+/HER2- metastatic breast cancer.
Olema Pharmaceuticals director Cyrus Harmon reported open-market sales totaling 25,000 common shares across two trading dates in September 2025, reducing his direct holdings from 754,140 to 744,140 shares and his indirect holdings (via Harmon Family Investors LLC, which he manages) from 120,114 to 117,028 shares. The reported weighted-average sale prices ranged from about $8.02 to $8.37, with specific weighted averages of $8.04 and $8.33 for direct sales and $8.08 and $8.32 for indirect sales. The Form 4 discloses the manager relationship for the indirect holdings and provides ranges and weighted averages for the trades.
Olema Pharmaceuticals (OLMA) filed a Form 144 proposing the sale of 13,086 common shares. The sale is to be executed through Fidelity Brokerage Services with an approximate aggregate market value of $108,977.56 and an intended sale date of 09/18/2025. The company reports 68,634,329 shares outstanding, making the proposed sale a small portion of outstanding stock. The filer acquired 10,000 shares as founders shares on 03/20/2007 (compensation) and 3,086 shares in an open-market purchase on 06/30/2014 (cash). The filing also discloses recent sales on 09/16/2025: 10,000 shares by Cyrus L. Harmon for $80,362.60 and 1,914 shares by Harmon Family Investors LLC for $15,464.28. The filer certifies no undisclosed material adverse information.
Olema Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 11,914 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $95,826.88. The filing lists approximately 68,634,329 shares outstanding and an approximate sale date of 09/16/2025 on the NASDAQ. The shares being offered consist of 10,000 founder shares acquired on 03/20/2007 (recorded as compensation) and 1,914 shares purchased in the open market on 06/30/2014 for cash. The filer certifies no undisclosed material adverse information about the issuer and references Rule 10b5-1 plan language if applicable.
Olema Pharmaceuticals, Inc. reported that it has entered into a new clinical trial collaboration and supply agreement with Pfizer Inc. to study a combination treatment for certain breast cancers. The companies plan a Phase 1b/2 study evaluating the safety and combinability of palazestrant with atirmociclib, Pfizer’s investigational, highly selective CDK4 inhibitor, in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
Under the agreement, Pfizer will supply atirmociclib for the study, while Olema will lead the conduct of the trial. All clinical data and inventions related to the combined use of atirmociclib and palazestrant will be jointly owned, and Olema will retain full global commercial and marketing rights to palazestrant. This is the second clinical trial agreement between the two companies, following an earlier collaboration formed in November 2020.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.
For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.